Article
Cardiac & Cardiovascular Systems
Stancu Alma, Debourdeau Eloi, Vazquez Lea, Coussirou Julie, Matagne Valerie, Grassi Pierre, Werner Hilgers, Girard Philippe, Zammit Christine, Debourdeau Philippe
Summary: Lung cancer patients treated with immune-checkpoint inhibitors (ICIs) have an increased risk of venous thromboembolism (VTE), which negatively impacts survival. The current VTE prediction models do not perform well in this population.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS
(2022)
Article
Oncology
Annie Apple, Lauren Prescott, Marc Robinson, Kendall Shultes, Alaina Brown
Summary: Notifying providers of a patient's Khorana score improves compliance with American Society of Clinical Oncology guidelines for venous thromboembolism chemoprophylaxis among chemotherapy patients.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2022)
Article
Cardiac & Cardiovascular Systems
Shuangping Li, Pengfei Gao, Jiayong Qiu, Xuegai He, Yimin Mao
Summary: The study found that D-dimer is an independent risk factor for VTE in newly diagnosed advanced lung cancer patients. The modified Khorana score incorporating D-dimer has a higher predictive value for the occurrence risk of VTE and can more fully identify high-risk groups when the score is >= 2.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS
(2021)
Article
Hematology
Magdolna Nagy, Alejandro Pallares Robles, Mayken Visser, Thomas Koeck, Vincent ten Cate, Arina J. ten Cate-Hoek, Stephan Schwers, Stefan Heitmeier, Hugo ten Cate, Philipp S. Wild, Henri M. H. Spronk
Summary: This study found that FXIa levels were elevated in patients with acute VTE and were associated with recurrent VTE, suggesting a significant risk contribution of FXI activation to VTE. The findings support the use of FXIa inhibition in the setting of acute VTE.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2023)
Review
Pharmacology & Pharmacy
Akari Nishimura, Yoshiaki Ikeda
Summary: This study investigated the usefulness of the Khorana score for predicting venous thromboembolism, finding that while the prediction might be useful, most VTE patients fall into the low- and intermediate-risk groups. Therefore, a comprehensive evaluation based on clinical conditions is necessary regardless of the risk classification using the Khorana score.
YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN
(2021)
Article
Urology & Nephrology
Umar Iqbal, Ahmed S. Elsayed, Sadat Ozair, Zhe Jing, Gaybrielle James, Qiang Li, Ahmed A. Hussein, Khurshid A. Guru
Summary: The Khorana score underestimated the risk of VTE after RARC and showed poor accuracy, highlighting the need for procedure-specific tools to estimate VTE risk after RARC.
JOURNAL OF ENDOUROLOGY
(2021)
Review
Oncology
R. A. L. Willems, N. Michiels, V. R. Lanting, S. Bouwense, B. L. J. van den Broek, M. Graus, F. A. Klok, B. Groot Koerkamp, B. de Laat, M. Roest, J. W. Wilmink, N. van Es, J. S. D. Mieog, H. ten Cate, J. de Vos-Geelen
Summary: In the past, patients with pancreatic ductal adenocarcinoma often underwent immediate surgery for tumor resection. Now, more and more patients receive chemotherapy (radiotherapy) before surgery. It is known that pancreatic cancer patients have a higher risk of developing thrombosis. However, the incidence of thrombosis in patients with pancreatic cancer during neoadjuvant chemotherapy is not well-studied. Few studies have investigated VTE incidence in this population, and it is unclear if these patients should use perioperative thromboprophylaxis. This narrative review summarizes the current evidence.
Article
Immunology
Junshuai Xue, Delin Ma, Jianjun Jiang, Yang Liu
Summary: Various immune/inflammatory indicators have been studied for their diagnostic and prognostic value in venous thromboembolism (VTE), with the neutrophil/lymphocyte ratio (NLR) showing promising predictive capability. Further investigations are needed to determine the reliability and stability of other indicators such as platelet/lymphocyte ratio (PLR) and systemic immune/inflammatory index (SII). Overall, this review provides new insights and clinical guidance for the diagnosis and treatment of VTE.
JOURNAL OF INFLAMMATION RESEARCH
(2021)
Article
Hematology
Takahito Suzuki, Reina Hori, Kazutaka Takeuchi, Ryo Yamamura, Hiromasa Katoh, Yoshihiro Noji, Masato Yamaguchi, Susumu Fujino
Summary: The study found a high incidence of VTE in patients with PDAC in Japan, with the VTE group having significantly more patients with a body mass index >25 kg/m(2) and a higher rate of chemotherapy compared to the non-VTE group. However, VTE may not have a significant effect on the prognosis of PDAC.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
(2021)
Article
Oncology
Gaoming Wang, Ludi Yang, Jinli Gao, Huiling Mu, Yanxiang Song, Xiaohua Jiang, Bo Chen, Ran Cui
Summary: High expression of ASXL2 in pancreatic cancer is associated with poor overall survival and is mainly involved in inflammatory response and epithelial mesenchymal transition. Patients with high ASXL2 expression are more likely to benefit from certain treatment modalities such as immune checkpoint blockade and specific chemotherapeutic drugs.
FRONTIERS IN ONCOLOGY
(2021)
Article
Peripheral Vascular Disease
Ya Qin, Xiao Liang, Hongshuai Wu, Xia Sun, Shuai Yan, Nanyao Wang, Ming Yuan, Qiong Wang, Dan Wu
Summary: The study aimed to establish an effective model to identify high-risk VTE in metastatic lung cancer patients. Adenocarcinoma, D-dimer, and the Khorana score were found to be independent risk factors for VTE in the development cohort. The modified Khorana score showed greater accuracy in predicting VTE in patients with newly diagnosed stage IV lung cancer compared to the Khorana score.
Review
Oncology
Sara Moufarrij, Dib Sassine, Derman Basaran, Elizabeth L. Jewell
Summary: This study aimed to assess the risk of venous thromboembolism (VTE) in patients with ovarian cancer undergoing neoadjuvant chemotherapy (NACT). A literature review identified several studies indicating a higher risk of VTE in some patients receiving NACT, highlighting the need for better risk stratification. Therefore, the authors suggest considering VTE prophylaxis in ovarian cancer patients undergoing NACT.
GYNECOLOGIC ONCOLOGY
(2023)
Article
Hematology
Noori A. M. Guman, Roos J. van Geffen, Frits Mulder, Thijs F. van Haaps, Vahram Hovsepjan, Mariette Labots, Geert A. Cirkel, Filip Y. F. L. de Vos, Albert J. ten Tije, Laurens Beerepoot, Vivianne C. G. Tjan-Heijnen, Hanneke W. M. van Laarhoven, Paul Hamberg, Annelie J. E. Vulink, Maartje Los, Aeilko H. Zwinderman, Bart Ferwerda, Martijn P. J. K. Lolkema, Neeltje Steeghs, Harry R. Buller, Pieter W. Kamphuisen, Nick van Es
Summary: The study compared the predictive performance of Khorana, PROTECHT, and 5-SNP scores in identifying cancer patients at higher risk of VTE. Results showed that PROTECHT or 5-SNP scores were not superior to the Khorana score, and the majority of cancer patients who developed VTE within 6 months were not identified by these scores. Future directions may include combined clinical-genetic scores for cancer-associated VTE prediction.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2021)
Article
Hematology
Yohei Hisada, Kenison B. Garratt, Anaum Maqsood, Steven P. Grover, Tomohiro Kawano, Brian C. Cooley, Jonathan Erlich, Florian Moik, Matthew J. Flick, Ingrid Pabinger, Nigel Mackman, Cihan Ay
Summary: This study investigated the association of active Lys-PG in plasma and VTE in pancreatic cancer patients, as well as the impact of human pancreatic tumors expressing Lys-PG on venous thrombus resolution in mice. The results suggest that Lys-PG may contribute to the development of VTE in pancreatic cancer.
Review
Oncology
Lu Ye, Li Cai, Yonghui Fu, Debao Zhuang, Xiaoqing Hu, Youkun Jie
Summary: This study revealed that the prevalence of chemotherapy-related VTE in ovarian cancer patients was approximately 9%. Significant risk factors for chemotherapy-related VTE were identified, which may contribute to targeting potentially preventative measures for VTE in ovarian cancer. The prognostic value of VTE in ovarian cancer patients receiving chemotherapy remains inconclusive and further research is needed.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2021)
Article
Medicine, General & Internal
Juwhan Choi, Jee Youn Oh, Young Seok Lee, Kyung Hoon Min, Jae Jeong Shim, Sue In Choi, Dong Won Park, Chan Kwon Park, Eun Joo Kang, Hwan Seok Yong, Bong Kyung Shin, Hyun Koo Kim, Sung Yong Lee
Summary: This study suggests that adjuvant chemotherapy can significantly reduce the recurrence rate and risk of mortality in patients with stage IB NSCLC with high-risk factors, particularly for patients with visceral pleural involvement or vascular invasion.
KOREAN JOURNAL OF INTERNAL MEDICINE
(2022)
Article
Oncology
Yoon Ji Choi, Jung Yoon Choi, Ju Won Kim, Ah Reum Lim, Youngwoo Lee, Won Jin Chang, Soohyeon Lee, Jae Sook Sung, Hee-Joon Chung, Jong Won Lee, Eun Joo Kang, Jung Sun Kim, Taekyu Lim, Hye Sook Kim, Yu Jung Kim, Mi Sun Ahn, Young Saing Kim, Ji Hyun Park, Seungtaek Lim, Sung Shim Cho, Jang Ho Cho, Sang Won Shin, Kyong Hwa Park, Yeul Hong Kim
Summary: The K-MASTER project aims to be a Korean national precision medicine platform that screens actionable mutations in solid tumor patients through analyzing NGS. The comparison between NGS panel and orthogonal methods showed a different degree of agreement for each genetic alteration, but generally had a high agreement rate.
CANCER RESEARCH AND TREATMENT
(2022)
Article
Oncology
Kyoungmin Lee, Eunjin Noh, Seok Joo Moon, Yoonjung Yoonie Joo, Eun Joo Kang, Jae Hong Seo, In Hae Park
Summary: Statins may have synergistic effects with endocrine therapy with the mTOR inhibitor everolimus and improve survival in patients with HR+ metastatic breast cancer.
Article
Oncology
Kyoungmin Lee, In Hae Park, Sang Cheul Oh, Jae Hong Seo, Min Ji Jeon, Eun Sang Yu, Dae Sik Kim, Chul Won Choi, Ah-reum Lim, Myung Han Hyun, Ju Won Kim, Jwa Hoon Kim, Yoon Ji Choi, Soohyeon Lee, Kyong Hwa Park, Yeul Hong Kim, Jung Yoon Choi, Jung Sun Kim, Se Ryeon Lee, Hwa Jung Sung, Eun Joo Kang
Summary: This study investigated the perception and safety profile of COVID-19 vaccines in cancer patients. The results showed that despite concerns about vaccine-related adverse events and negative effects on cancer treatment, the vaccines were well tolerated by cancer patients, with a safety profile consistent with that of the general population.
Article
Oncology
Yun-Gyoo Lee, Eun Joo Kang, Bhumsuk Keam, Jin-Hyuk Choi, Jin-Soo Kim, Keon Uk Park, Kyoung Eun Lee, Keun-Wook Lee, Min Kyoung Kim, Hee Kyung Ahn, Seong Hoon Shin, Hye Ryun Kim, Sung-Bae Kim, Hyo Jung Kim, Hwan Jung Yun
Summary: Although women account for 30% of head and neck cancer cases, they have been underrepresented in clinical trials. This study aimed to compare treatment modalities and outcomes between male and female patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC). The results showed no significant differences in treatment strategies and overall survival between the sexes, suggesting no apparent sex-based disparity in the treatment and outcomes of LA-HNSCC.
Article
Oncology
Jiyun Lee, Sehhoon Park, Hyun Ae Jung, Se-Hoon Lee, Seyoung Seo, Sung-Bae Kim, Ji-Won Kim, Keun-Wook Lee, Eun Joo Kang, Ju Won Kim, Yoon Ji Choi, Byoung-Yong Shim, Ho-Jung An, Lee Chun Park, Seong Hoon Shin, Jae-Joon Kim, So Yeon Oh, Min Kyoung Kim, Myung-Ju Ahn
Summary: In this study, the combination of docetaxel-PM and trastuzumab-pkrb showed promising antitumor activity with an objective response rate of 69.8%, disease control rate of 93.0%, median progression-free survival of 7.9 months, median duration of response of 6.7 months, and median overall survival of 23.3 months. Treatment-related adverse events were managed with temporary discontinuation, permanent discontinuation, or dose reduction.
Article
Dentistry, Oral Surgery & Medicine
Eun Joo Kang, Seok-joo Moon, Kyoungmin Lee, In Hae Park, Jung Sun Kim, Yoon Ji Choi
Summary: Using a nationwide population cohort database, this study found that poor dental health, especially missing teeth, is highly associated with an increased risk of various cancers.
Article
Oncology
Byeong Seok Sohn, Jeongeun Kim, Miso Kim, Jung Yong Hong, Jieun Lee, Song Ee Park, Hyojeong Kim, Hyo Jin Lee, Eun Joo Kang, Soon Il Lee, In Hee Lee, Seok Jae Huh, Jeongmin Jo, Ho Young Kim
Summary: This study aimed to investigate treatment outcomes of Korean patients with advanced/metastatic Extramammary Paget's disease (EMPD). The results showed that the combination of systemic chemotherapy and trastuzumab had longer survival than trastuzumab monotherapy or conventional platinum- or taxane-based chemotherapy.
Article
Oncology
Changhwan Sung, Jinhyeon An, Soohyeon Lee, Jaesoon Park, Kang Seon Lee, Il-Hwan Kim, Ji-Youn Han, Yeon Hee Park, Jee Hyun Kim, Eun Joo Kang, Min Hee Hong, Tae-Yong Kim, Jae Cheol Lee, Jae Lyun Lee, Shinkyo Yoon, Chang-Min Choi, Dae Ho Lee, Changhoon Yoo, Sang-We Kim, Jae Ho Jeong, Seyoung Seo, Sun Young Kim, Sun-Young Kong, Jung Kyoon Choi, Sook Ryun Park
Summary: The study investigates risk factors for immune-related adverse events (irAEs) in cancer patients treated with checkpoint inhibitors. It found that irAE samples had lower contribution of neutrophils and identified a genetic variant in TMEM162 associated with higher B cell counts and suppression of regulatory T cells. Machine learning models were developed for irAE prediction and validated in an independent cohort.
Article
Otorhinolaryngology
Dong Hyun Kim, Yoojoo Lim, Chan-Young Ock, Gahee Park, Seonwook Park, Heon Song, Minuk Ma, Mohammad Mostafavi, Eun Joo Kang, Myung-Ju Ahn, Keun-Wook Lee, Jung Hye Kwon, Yaewon Yang, Yoon Hee Choi, Min Kyoung Kim, Jun Ho Ji, Tak Yun, Sung-Bae Kim, Bhumsuk Keam
Summary: This study found that TIL infiltration in cancer and stromal areas was generally low in recurrent or metastatic adenoid cystic carcinoma. However, patients with higher stromal TIL density exhibited longer progression-free survival with axitinib treatment.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
(2023)
Article
Oncology
M. Kim, S. J. Shin, J. L. Lee, W. K. Bae, Y. J. Choi, J. Youk, C. Y. Ock, H. J. Lee, J. H. Byun, S. Kim, H. Song, K. H. Park, B. Keam
Summary: The efficacy and safety of trastuzumab-pkrb in combination with paclitaxel were evaluated in HER2-positive recurrent or metastatic urothelial carcinoma patients. The study showed promising efficacy and manageable toxicity profiles of this combination treatment in this type of cancer patients.
Article
Public, Environmental & Occupational Health
Eun Joo Kang, Yun-Gyoo Lee, Minji Koo, Kyoungmin Lee, In Hae Park, Jung Sun Kim, Yoon Ji Choi
Summary: HNCA survivors in Korea have a higher risk of developing cardiovascular disease or stroke. Patients with hypertension, diabetes mellitus, and hyperlipidemia are at a significantly higher risk of CVD, while those with three underlying diseases are at a higher risk of stroke.
HEALTH SCIENCE REPORTS
(2022)
